Recruiting

Tranexamic Acid

Sponsor:

Mayo Clinic

Code:

NCT06832878

Conditions

Arthroplasty

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Oral Tranexamic Acid

Study Details

Brief summary:

The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.

Conditions

Arthroplasty

Study ID

NCT06832878

Start date

Jun 1, 2026

Status verified date

Jul, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria

  • Adults aged > 18 years (All women of childbearing potential undergo pregnancy testing prior to THA as per our institutional protocol)
  • Written informed consent
  • Patients undergoing primary THA diagnosis of end-stage osteoarthritis
  • Patients receiving spinal anesthesia
  • Patients being discharged on postoperative day 1

Exclusion Criteria

  • Patients with a TXA allergy
  • Patients undergoing revision procedures
  • Patients undergoing primary THA for a diagnosis other than end-stage osteoarthritis
  • Patients receiving general anesthesia
  • Patients being discharged on the same day of surgery
  • Cancer patients
  • Patients with a history of prior VTE event
  • Patients on preoperative anticoagulants other than ASA
  • Pregnant patients (All women of child bearing potential undergo pregnancy testing prior to THA as per our institutional protocol)
  • Female patients who are on hormonal contraception
  • Patients with history of retinal vein or artery occlusion

Study Design

Enrollment

101 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Oral tranexamic acid

no intervention: Control Group

Interventions

Oral Tranexamic Acid

Subjects will receive a 1.95 g dose of oral TXA at the following timepoints: (1) following ambulation, (2) postoperative day 1, (3) postoperative day 2, and (4) postoperative day 3

Primary outcome measure

  • Visual Analog Score [ Time Frame: Baseline, 3 days postoperative, 2 weeks, 6 weeks, 12 weeks ]
  • Hip Disability and Osteoarthritis Outcome Score (HOOS) for Joint Replacement (JR) [ Time Frame: Baseline, 3 days postoperative, 2 weeks, 6 weeks, 12 weeks ]

Central Contacts and Locations

Locations

Mayo Clinic in Arizona

Recruiting

Scottsdale, Arizona, United States, 85259

Contacts

Saad Tarabichi, MD

267-694-5292tarabichi.saad@mayo.edu

Principal Investigator:

Joshua Scott Bingham

More Information

Sponsor

Mayo Clinic

Last update posted

Aug 10, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-08-10.